Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAVALRY: Capivasertib, Venetoclax and mini-hyperCVD for ALL/LBL
NCT07294677Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- Mar 2026
- Primary completion
- Mar 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capivasertib in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) (6 cohorts), sponsored by University of Chicago. Primary endpoints: Safety of the combination of mini-hyperCVD and venetoclax plus capivasertib, Recommended Phase 2 Dose and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
capivasertib
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT07294677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07294677.